Vanguard Global Advisers
DYN icon

Vanguard Global Advisers’s Dyne Therapeutics DYN Stock Holding History

Vanguard Global Advisers’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.2M Sell
54,137
-2,255
-4% -$41.9K ﹤0.01% 1623
2026
Q1 		$1.02M Buy
+56,392
New +$972K ﹤0.01% 1644

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Global Advisers's DYN Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Dyne Therapeutics (DYN) stake by 4% in Q2 2026, selling an estimated $41.9K and leaving 54,137 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1623.

Vanguard Global Advisers first reported a position in DYN in Q1 2026 and has held it in 2 quarters since. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Vanguard Global Advisers held 54,137 shares of Dyne Therapeutics worth $1.2M as of Q2 2026.
  • Vanguard Global Advisers sold 2,255 Dyne Therapeutics shares in Q2 2026, an estimated $41.9K.
  • Dyne Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1623 holding.
  • Vanguard Global Advisers first reported a position in Dyne Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.